Taken together, the present study reinforces the notion that GSK3β is a potential therapeutic target in ESCC, thereby including this as another tumor type susceptible to GSK3β-targeted therapy19,21. This evidence concerns the gene GSK3B and esophageal squamous cell carcinoma.